Contact Us     Privacy     Terms of Use                                                                © Copyright Pharma Market Research Conference 2011.  All Rights Reserved.
Day 1, Wednesday, February 4, 2015
General Session:
7:15 - 8:15
Registration & Networking Breakfast in Exhibition Hall
___________________________________________________________________________________________________
8:15 - 8:30
Chairpersons’ Opening Remarks
___________________________________________________________________________________________________
8:30 - 9:10
Keynote: Unlocking Brand Potential: A Patient-Centric Approach
Jon Congleton
, Senior Vice President & General Manager, Global CNS, Teva
___________________________________________________________________________________________________
9:10 - 9:50
Keynote: Topic TBA
TBA
___________________________________________________________________________________________________
9:50 - 10:50
Networking & Refreshments in Exhibition Hall
___________________________________________________________________________________________________
10:50 - 11:30
Reaction to Keynote Presentations By Advisory Board Members
Praveen Advani
, Executive Director, Customer Insights Oncology - IO, Bristol-Myers Squibb
Lisa Courtade, Executive Director, Global Market Research Excellence, Merck
Sandipa Dublish, Sr. Director Global MR, Alexion Pharmaceuticals
Steve Girling, President, Ipsos Healthcare
Stuart Greenberg, Deputy Director, Global/Oncology Market Research, Bayer
Anne Hale, US Specialty Care Lead – Business Analytics & Insights, Pfizer
Grace Samoil Reynolds, Head Market Insights, Celgene
David Rosen, Executive Director, Forecasting, Analytics & Market Research, Purdue Pharmaceuticals
___________________________________________________________________________________________________
11:30 - 12:20
Networking Roundtable Discussions
ROUNDTABLE
1
Opportunities in Global Market Research
Frank Wang
, Senior Director, Global Business Insights Oncology, EMD Serono
ROUNDTABLE
2
“Do It Yourself” Analytics
Wasse Alemayehu
, Director, Shire Pharmaceuticals
ROUNDTABLE
3
What Truly Drives Physicians Behavior Beyond Efficacy and Safety of the Products and How Does One Go About Diving
Deeper Behind the Veil?
Aaron Furtado
, Senior Director, Business Planning, Market Research, & Business Analytics, Ipsen
ROUNDTABLE
4
Topic TBA
John Vieira
, Sr. Director, Global Brand Strategy, Daiichi Sankyo
ROUNDTABLE
5
Challenges in Global Forecasting
Stephen Murdock
, Senior Director, Global Strategic Market Insights, Millennium Pharmaceuticals, Takeda Oncology
Rafaat Rahmani, President, Lifescience Dynamics Limited
ROUNDTABLE
6
Topic TBA
Michael McClellan,
Associate Director, Global New Products Market Research, Eisai
ROUNDTABLE
7
Integrating Customer Insights into Clinical Trial Recruitment and Enrollment
Jeff Jamer
, Director, Global Market Research Excellence, Merck
ROUNDTABLE
8
TBA
   
12:20 - 1:35
Networking Luncheon
___________________________________________________________________________________________________
1:40 - 2:15
Participants may choose 1 of 4 concurrent tracks.
TRACK A
Performance of Biosimilars in Key Markets and Innovator Defense Strategies
Rich McCloud
, Director, Pfizer

•        What is the penetration rate of Biosimilars in key markets?
•        In more detail, how is the first MaB peforming in Europe over time?
•        What are some of the innovator defense strategies that are employed to defend market share?
___________________________________________________________________________________________________
TRACK B
Successful Strategic Decision-Making Frameworks for Development Compounds Using a Zero Research Model
Steve Girling
, President, Ipsos Healthcare
Client Co-Presenter TBA
___________________________________________________________________________________________________
TRACK C
Global Online Patient Communities 2015 – Technology Spread and Experience Have Made This Possible
Donna Simpson
, Principal, Segmedica
Michelle Soto, Senior Project Director, Segmedica
___________________________________________________________________________________________________
TRACK D
Big Data Analytics in the Pharmaceutical Industry: Leading the Analytics Revolution
Abhilash Davé, PhD
, Principal, Strategic Research Insights, Inc. (SRI)
Sudhakar Mandapati, Principal, Strategic Research Insights, Inc. (SRI)
Client Co-Presenters TBA

Strategic Research Insights is aggressively leading the analytics revolution in the Pharmaceutical and Biotech Industry utilizing Big Data
(EMR, Claims, Registry) for multiple clients, and has been nominated for awards. The presentation identifies some of the best practices in
Big Data Analytics. Additionally, the authors highlight key metrics that can be easily gleaned from EMR and Claims data to successfully
measure product performance. Another major advance is identification of opportunities and leverage points predictive modeling. The
research will be presented with one or more clients.
___________________________________________________________________________________________________
   
2:20 - 2:55
Participants may choose 1 of 4 concurrent tracks.
TRACK A
Product Launch and the MR Needed – Understanding the “Behind the Scenes” as a Tool to Deliver the Winning Proposal
Magda Schoeneich
, Associate Director Insights Generation Neuroscience, Janssen
___________________________________________________________________________________________________
TRACK B
The Moment is the Medium: Human-Centric Research in the Digital Age
Laura Barry
, Senior Director, Customer Insights, Analytics, and Experiences, AbbVie
Sal Zerilli, Vice President Social Science, in-sync
Jedd Davis, SVP, Media, Publicis Health Media

The past two decades of digital media innovation have caused fundamental changes in marketing across all industries, including
healthcare. These changes have pressured Market Researchers on both sides of the client-supplier relationship to rethink the kinds of
methods we use, the kinds of data we pursue, and the roles we play for our employers and within the industry. In today’s media
environment, change and complexity define the new normal for all of us. Unenviably, we often need to cope with change and complexity by
doing more with less. Ugh. In this session, a supplyside researcher (in-sync) and a media strategist (Publicis Health Media) will co-present a
case study of how we successfully responded to these dynamics by leveraging “old” research methods and social science ideas to disrupt
and improve the media planning process for one of the largest healthcare brands in the world. We will walk the audience through a blinded
review of our process, emphasizing five factors that were essential to our success: (1) focusing on moments where human-centric and
business-centric needs intersect, (2) re-thinking and re-using “old” ideas and methods for “new” purposes, (3) employing multidisciplinary
teams, (4) integrating qual-quant methods, and (5) developing supplier client partnerships in Research and Development efforts to solve
complex problems endemic to the “digital age.”
___________________________________________________________________________________________________
TRACK C
Are You My Patient? Using Patient Trigger Studies to Determine if Your Messaging is On Target
Katy Palmer
, Managing Director, Healthcare, Market Strategies
___________________________________________________________________________________________________
TRACK D
Co-Constructing the Ideal Doctor-Patient Dialogue: Bridging the Gaps Between KOL Best Practices and Community-Level
Realities
Kaity Arctander
, Senior Analyst, Linguistic Insights and Analytics, Verilogue
Jeff Troy, Director, Client Services, Verilogue

All pharmaceutical brands employ a partnership with Key Opinion Leaders (KOLs) to inform their strategies throughout the product lifecycle.
While these advisory boards provide a wealth of real-world knowledge and insights about the marketplace, they further highlight the vast
gap that exists between the communication tactics and interaction styles of KOLs versus busy community-level physicians. In this session
you will learn about a unique engagement encompassing Advisory Board listening workshops focused on community-level interactions,
linguistic analysis of KOL-Patient dialogue recordings, and strategic development of physician and patient communication tools. This
success story divulges the “secret sauce” of how to leverage KOLs as mentors to community physicians by co-constructing the ideal
conversational flow.
___________________________________________________________________________________________________
   
3:00 - 3:35
Participants may choose 1 of 4 concurrent tracks.
TRACK A
Dimensions: A Better, More Efficient Route to Improving Your ROI- Greater Customer Understanding by Identifying Their
Unmet Needs
Mitchel Horowitz
, Methodologist, Partner, Lieberman
Sabera Hyderally, EVP, Lieberman
Elaine Melilo, Manager, Global Customer Insights Surgical Solutions, Covidien

Lieberman’s Dimensions methodology pinpoints the relative desirability of individual features and feature combinations at a price. While it
has elements in common with standard preference modeling techniques like SIMALTO, Dimensions is pragmatically focused on the vital
“hierarchy of preferences” necessary for a successful launch or restage. With Dimensions, market efforts can be calibrated to perfectly
match real world preferences.
___________________________________________________________________________________________________
TRACK B
Brand Improv: Creating Strategic Empathy for Brand Teams
Steve Martino
, Co-Managing Partner, M Health
John Surie, Customer Insight Director, M Health

Brand Improv is a novel workshop technique that uses actors to literally bring research findings to life in order to help brand teams
recognize new strategic opportunities hidden in the research they commission.  

Brand Improvs are usually given in rented theatre space as one-day research-to-strategy workshops involving a small team of researchers,
brand marketers and professional actors. The actors, who are carefully prepped in advance, translate a defined set of market research
insights into flesh-and-blood scenarios that unfold right before the eyes of the brand team. The idea is to make the insights as experiential
as possible in order to create strategic empathy. That is, enabling strategists to feel what their customers feel. By then guiding the brand
team through well-structured ideation exercises, the research insights and the improvisations that bring them to life act as powerful stimuli
for break-through strategic thinking.
___________________________________________________________________________________________________
TRACK C
Good Guidelines, Bad Guidelines:  Why, When, and How Payers Decide to Adopt or Ignore Guidelines in Setting Formularies
and Utilization Management Policies
Roger Green
, President/CEO, RG+A
Robert Kritzler, M.D., Deputy Chief Medical Officer, Care Management, Johns Hopkins HealthCare LLC

Historically, healthcare stakeholders have viewed treatment guidelines as one path to assuring consistent application of high-quality
healthcare. In theory, utilizing guidelines guarantees excellent care and a positive cost-benefit profile.In practice, it has never been this
simple. Development and enforcement of appropriate guidelines have always presented significant challenges to healthcare systems and
insurers. Over the past year, the issues has become more challenging, as an explosion of specialty drug spending has made it impossible
for health systems to afford therapies that might prove cost-beneficial in the long run.

Against this background, the application of guidelines has become increasingly controversial and inconsistent.  Some professional societies
have begun to promulgate cost-sensitive guidelines. At the same time, some insurers claim that they will create or support guidelines that
focus even more strongly on cost management in specialty pharmaceuticals. In this session, Dr. Kritzler and Mr. Green will report on a
series of on-line bulletin boards conducted with payers nationwide that address changing perspectives and use regarding guidelines, and a
study evaluating current utilization trends. Also, they will discuss how developments in HCV and multi-specialty agent regimens in oncology
and hematology are reshaping how health plans monitor and manage these categories.
___________________________________________________________________________________________________
TRACK D
Leveraging EMR Data to Better Understand Local Market Potential and the Deployment of Commercial Resources
Jim Charnetski
, Practice Lead, Commercial Analytics & Effectiveness, Quintiles

Historically, EMR and HEOR data has resided within the clinical side of pharma organizations. However, commercial organizations are
beginning to adopt and leverage this information in the commercial space to drive decisions around disease state market potential, patient
and physician targeting, treatment pathway/patient journey insights, and the local deployment of commercial resources. A key focus point of
this approach is the ability to understand the degree to which local geographies are adopting preferred disease management protocols for
given disease states and defined patient cohorts. Through this analytical approach, clients can identify areas where a “treatment deficit”
exists relative to the established standards, and deploy greater education and resource activities against these geographies to reduce that
gap and deliver greater health outcomes to patients.
___________________________________________________________________________________________________
   
3:35 - 4:35
Networking & Refreshments in Exhibition Hall
___________________________________________________________________________________________________
4:35 - 5:10
Participants may choose 1 of 4 concurrent tracks.
TRACK A
The Human Truth Behind Health Management: How Merck Leveraged Social Psychology and Behavioral Economics to Inspire
Experience Design
Anna Kravets
, Director, External Partner Platform, Merck

Merck sought to drive deep consumer empathy across the entire organization and brand portfolio. Despite having access to a treasure
trove of data outlining consumers' rational perspectives and behaviors around health, Merck recognized that they needed to know more
about the underlying psychological motivations that drive decisions to be either proactive or reactive regarding managing one's health. The
Merck team knew that building an understanding of the roles various dimensions and tools play in health management decisions would
enable the development of design personas that inform key strategic decisions, M&A, and new business model exploration.
This presentation will reveal:
•        How Merck gained a clearer perspective on consumers through uncovering non-conscious drivers
•        How understanding the consumer journey brings meaningful design opportunities into view
•        How building consumer empathy internally can bring clarity to business objectives
•        How understanding consumers' value orientations and personality traits can inspire personas to fuel experience design
___________________________________________________________________________________________________
TRACK B
Maximizing Messaging Utility
Michael Heasley
, Partner and Chief Research Officer, Evolution Consulting
Krystyna Litton, Consultant, Evolution Consulting

Through the analysis of historic data and the application of marketing theory, it is possible to determine a set of related functions that
describes both the Value and the Impact of a product’s message over time.  We will review the theory, closely examine a case-study that
shows this model in action, and discuss ways to make this theory actionable to your or your customer’s brand.
___________________________________________________________________________________________________
TRACK C
Glass Half Full or Half Empty: How Google Glass Gave Insight in Landmark Healthcare Market Research Study
Katy Irving
, Associate Director, HRW

There is a lot of hype around wearable technology, but what does it really deliver for market research?  In this presentation, HRW will
showcase the results from a first-of-its-kind series of adapted ethnography research projects conducted with physicians and patients using
Google Glass; and how this allowed us to literally see things from our participants’ perspective.  
The session will:
•        Introduce the uninitiated to Google Glass ‘in the flesh’ and demonstrate its multi-method data capture
•        Offer an honest review of the unique benefits and limitations of Glass from our experience with real respondents
•        Discuss how it compares with other methods (both ‘traditional’ and digital)
•        Highlight where/how it is best utilized to add value and share feedback from pharma clients on the impact it has had for them
______________________________
_____________________________________________________________________
TRACK D
Top Chef: Eight Ingredients to Being Indispensable
Rayna Herman
, Principal, SVP Sales and Marketing, Health Strategies Group

Answering member’s requests for a topic on the strategic leader’s role & fostering strategic partnerships, this workshop will provide a proven
recipe that empowers market researchers to move from data providers into business savvy advisors, strategically anticipating the needs of
their internal customers and championing a market research plan that generates product success. Participants will leave this hands-on
workshop feeling confident and empowered to expand their role using a cutting-edge eight-step process that provides actionable principles
to unlock greater levels of growth, innovation, and success for them. Each step identifies specific actions they can adopt to immediately
increase:
•         their ability to foresee the business needs of the team long before the rest of the team realizes them,
•         the level of reliance their internal stakeholders have on them, and
•         the team's perception of them as vital strategic leaders rather than reactive data providers.
___________________________________________________________________________________________________
   
5:15 - 6:15
Participants may choose 1 of 4 concurrent tracks.
TRACK A
Social Listening in Healthcare: What’s the Buzz?
Moderator: Lisa Courtade, Executive Director, Global Market Research Excellence, Merck
Seth Cohen, Associate Director, Strategic Insights & Analytics, Novartis
Trish Nettleship, Director, Social Media & Influence, UCB
Marjorie Reedy, Director, Global Market Research Excellence, Merck
___________________________________________________________________________________________________
TRACK B
Evolving Role of a Market Researcher in a Time of Change
Terri Boyd
, Procurement, Market Research, Janssen
Ted Finlay, Director of Market Research & Statistical Analysis, Merial
Kumar Kantheti, Senior Director, Portfolio Management, Global Development Division, Shionogi Inc
Anindita Niyogi, Director, Market Analytics - Specialty Care, Pfizer
Pamela Posnock, Director-Oncology Global Market Research & Analytics, Merck
___________________________________________________________________________________________________
TRACK C
De-Mystifying Franchise Strategy - How Pragmatic Approaches Can Help Brand Teams Prioritize and Win Whether They Are the
Dominant Incumbent or the New Kid on the Block
Moderator: Chris Schneider, SVP, Commercial Strategy and Forecasting, Ipsos Healthcare
Additional Panelists TBA
___________________________________________________________________________________________________
TRACK D
Industry and Agency Interaction Best Practices
Moderator: Rafaat Rahmani, President, Lifescience Dynamics
Renata Alves, Sr. Manager, Business Analytics and Insights, Pfizer
Stephen Murdock, Senior Director, Global Strategic Market Insights, Millennium Pharmaceuticals, Takeda Oncology
Mini Pinto, Global Customer Insights Director, Merck
Timothy Subotkowski, Senior Manager Global Market Research, Alexion

This symbiotic relationship with agency and industry will improve the chances of successful MR projects with positive ROI, protect our
profession from data fetchers. Therefore, we all as MR professional should aspire to be the extended team of our clients.
______
_____________________________________________________________________________________________
   
6:15 - 8:00
Evening Socializing Events! Casino Gaming, Reception & Networking
___________________________________________________________________________________________________
   
Day 2, Thursday, February 5, 2015
7:15 - 8:15
Registration & Networking Breakfast in Exhibition Hall
___________________________________________________________________________________________________
8:15 - 8:30
Chairpersons’ Opening Remarks (will occur within each separate track session)
___________________________________________________________________________________________________
8:30 - 9:05
Participants may choose 1 of 4 concurrent tracks.
TRACK A
Consumer Empathy: How Panadol Turned to the Mind to Reveal New Opportunities to Strengthen Its Relationship with
Consumers
Elizabeth Latoracca
, Global Insights Director, GlaxoSmithKline

Panadol is a brand that is iconic in the minds of Australians and many others around the world. It is used by grandparents, parents and
children alike. However, like many long-standing brands, it is at risk of becoming irrelevant in a market place that keeps changing with new
threats, new regulations and new consumers. Beginning in 2010, the brand had rarely reached normal levels of recognition and over the
past three years had only hit a normal level of recognition for one campaign while others were as low as only 20% of normal recognition
even after significant investment.

The team knew that it had to do something to maintain its prominence in the market place and solidify its defense against new entrants. The
team also knew it didn’t have a branding problem nor a creative problem. The brand itself is well-known and loved by consumers and the
creative was well planned and well executed. The team realized it had an empathy problem – it didn’t truly understand its audience’s deeper
emotions related to pain, drivers of behavior in choosing a pain reliever and what was truly at risk when it came to pain management.

The team’s solution: to establish a clear understanding of the consumer and to lead the team in developing a deeper sense of consumer
empathy. With this consumer empathy squarely in the minds of the brand team, the creative briefs were updated and new more emotional
campaign launched that immediately achieved normal levels of recognition with only a fraction of the investment. Today, the brand’s health
measures continue to move in the right direction and they remain prepared for a changing market place.
___________________________________________________________________________________________________
TRACK B
Topic TBA
Kantar Health
____________
_______________________________________________________________________________________
TRACK C
Does (VUCA) Volatility, Uncertainty, Complexity and Ambiguity Make Strategic Planning Obsolete?
Heath Gross
, Managing Partner, Sedulo Group

Over the last two decades military strategists have had to make significant changes to their planning process as they deal with the shift from
linear battlefields to combating guerrilla warfare and terrorism. Leveraging the VUCA framework, military strategists have overcome many of
the challenges associated with Volatility, Uncertainty, Complexity and Ambiguity.

In the private sector, corporations have experienced similar upheaval and uncertainty as innovative technology, and the shift to a global
economy, have dramatically increased the rate of change and the propensity for disruption.

Leveraging Heath's experience in both military and corporate strategy, we will discuss the value of the VUCA framework applied to
business.  Particularly, we will focus on how competitive intelligence can support strategic planning by minimizing the impact of Volatility,
Uncertainty, Complexity and Ambiguity.
___________________________________________________________________________________________________
TRACK D
Partnering for Insights
Amy Abel
, Senior Vice-President, Chief Commercial Officer, Adelphi Research
Carly Gibbons, Associate Director, Adelphi Research
Michelle Supsic, Senior Director, Adelphi Research
Ratna Wynn, Vice President, Adelphi Research
Client Co-Presenter TBA
___________________________________________________________________________________________________
9:10 - 9:45
Participants may choose 1 of 4 concurrent tracks.
TRACK A
Emotional insights – Uncovering and Leveraging the Hidden Drivers of Customer Behavior
Richard Kaminsky
, Director International Customer Insight Manager, Boehringer Ingelheim

Rich will lead a discussion of CI (customer insights), with a view toward enhanced identification and practical application, focusing on:
•        Customer-centric communication
•        Methodological and analytical design to optimize insights generation
•        Case study review from immunology, respiratory, metabolic and sexual health therapeutic areas
___________________________________________________________________________________________________
TRACK B
Unlock Real World, Real Time Patient Informatics
Dr. Jared Adams
, MD, PhD, Chief Medical Officer, Director of Product Development, Self Care Catalysts Inc
Leslie Jamison, EVP, Managing Director, Self Care Catalysts Inc
Client Co-Presenter TBA
___________________________________________________________________________________________________
TRACK C
Best Practices in Data Visualization, Dashboards & Analytics
Ganesh Kanumalla
, CEO, IQ 20/20
Client Co-Presenter TBA
___________________________________________________________________________________________________
TRACK D
Ongoing Customer Collaboration Leads to Better Outcomes
Regina Mercado
, Senior Manager Marketing Analytics & Business Insights, AbbVie
Kevin O’Shea, Manager Marketing Analytics & Business Insights, AbbVie
Corey Schwartz, Managing Director, Communispace Health
___________________________________________________________________________________________________
   
9:45 - 10:45
Networking & Refreshments in Exhibition Hall
___________________________________________________________________________________________________
   
10:45 - 11:20
Participants may choose 1 of 4 concurrent tracks.
TRACK A
Topic TBA
Michael Devinoff
, Executive Director, Forecasting, Epidemiology, & Predictive Analytics, Bristol-Myers Squibb
Anthony Pugliese, Director, Customer Insights & Analytics, Bristol-Myers Squibb
___________________________________________________________________________________________________
TRACK B
Gamification in Market Research
Anne Hale
, US Specialty Care Lead – Business Analytics & Insights, Pfizer
___________________________________________________________________________________________________
TRACK C
Condoms and Car Restraints – Can We Learn Anything About Compliance?
Joel Schindler
, Vice President, MarketVision Research
___________________________________________________________________________________________________
TRACK D
Topic TBA
Campbell Alliance
___________________________________________________________________________________________________
   
11:25 - 12:00
Participants may choose 1 of 4 concurrent tracks.
TRACK A
Struggling to Generate Maximum Value from EMR Data? Here Are Some of the Reasons Why - and How to Fix It
Simon Fitall
, Co-Founder & CEO, Galileo Analytics

Many companies have now acquired EMR data as a core source of clinical data. In a lot of cases we hear that the company isn’t satisfied
with the level of value they are deriving from the data. It is not that no value is being created, but that the value generating is not meeting
expectations. This presentation will illustrate some of the reasons behind these difficulties and will demonstrate, using case studies, a
solution that increases value generation for all EMR data sources.
___________________________________________________________________________________________________
TRACK B
Non-Adherence
John Mitchell
, Sr. Director, Healthcare Client Development, BuzzBack Market Research

Non-adherence causes economic loss of $300 billion dollars each year in the US, primarily in hospitalization costs for patients who would
have gotten better on medication. There are many behavioral factors like forgetting to take one’s medicine, improper dosing, inability to
afford medication, etc., that prevent adherence. Beyond those causes with a rational explanation, experts say that nearly half of non-
adherence is caused by something other than behavioral miscues. These include believing that “alternative” medicine will offer a better
outcome, emotional obstacles, resentment of the physician, of the pharmaceutical industry, etc. Additionally, low health literacy costs
between $100 and $200 billion annually in unnecessary sickness and its treatment. Many people simply do not understand what their illness
is and why, or how, to treat it.

BuzzBack will present an approach to understanding non-adherence from an emotional perspective, using some of its proprietary research
tools. We will also explore factors driving adherence, including issues around patient literacy and how it impacts non-adherence.

Attendees of this session will
-        Gain understanding of the issues surrounding Health Literacy and adherence
-        Be able to identify ways to overcome non-adherence, especially in emotional factors
-        Learn new techniques for revealing emotional factors driving behavior useful in communications development focused on improving
literacy.
___________________________________________________________________________________________________
TRACK C
Topic TBA
NAXION
___________________________________________________________________________________________________
TRACK D
TBA
___________________________________________________________________________________________________
   
12:00 - 1:10
Networking Luncheon
___________________________________________________________________________________________________
General Session:
1:10 - 1:20
Announcement of "Exhibitor Passport" Grand Prize Winner & Other Raffle Prize Winners
___________________________________________________________________________________________________
1:20 - 1:50
The Future of Market Research and Skill Sets Required for Future Market Researchers
Binita Bhattacharya
, Design Research Associate, BD Diagnostics
Rafaat Rahmani, President, Lifescience Dynamics Limited

•        Introduction and background
•        Current state of pharmaceutical & medical device market research in the USA and EU
•        How can the MR vendors deliver more to the Industry?
•        The way forward: MR vendor view
•        Challenges for the Industry and the MR vendors
•        The way forward: Industry view
•        Summary and takeaways
_____________________________________________________________________________
______________________
1:50 - 2:20
Towards True Patient Centricity – The Pharma Odyssey
Peter Simpson
, Principal, Segmedica
___________________________________________________________________________________________________
2:20 - 2:50
When You Need a Quick Read - Successful Approaches to Mobilizing Qual/Quant Insights at High-Speed
David Scowcroft
, SVP, Ipsos Health
Client Co-Presenter TBA
_____________________________________________________________________________
______________________
2:50 - 3:35
Summary and Key Takeaways By Advisory Board Members
Praveen Advani
, Executive Director, Customer Insights Oncology - IO, Bristol-Myers Squibb
Lisa Courtade, Executive Director, Global Market Research Excellence, Merck
Sandipa Dublish, Sr. Director Global MR, Alexion Pharmaceuticals
Steve Girling, President, Ipsos Healthcare
Stuart Greenberg, Deputy Director, Global/Oncology Market Research, Bayer
Anne Hale, US Specialty Care Lead – Business Analytics & Insights, Pfizer
Grace Samoil Reynolds, Head Market Insights, Celgene
David Rosen, Executive Director, Forecasting, Analytics & Market Research, Purdue Pharmaceuticals
___________________________________________________________________________________________________
3:35
Conference Concludes
___________________________________________________________________________________________________
   
Pre-Conference Workshops, Tuesday, February 3, 2015
[Separate Registration Required]
8:30 - 9:00
Registration and Networking Breakfast
___________________________________________________________________________________________________
9:00 - 10:45
Topic TBA
Roger Green
, President/CEO, RG+A
___________________________________________________________________________________________________
10:45 - 11:00
Networking Break
___________________________________________________________________________________________________
11:00 - 1:00
MR in the Context of Business Development and Licensing
Marianne Jaeger
, Ph.D., Methodologist, Lifescience Dynamics
Rafaat Rahmani, President, Lifescience Dynamics

•        How can MR support the BD&L process?
•        How can CI and payer discussions complement MR in this process?
•        How can MR, CI and Payer research input in the forecasting?
•        Valuation of an asset
___________________________________________________________________________________________________
1:00 - 2:00
Networking Luncheon
___________________________________________________________________________________________________
2:00 - 5:00
The Patient Journey Unplugged – An In-Depth and Interactive Workshop on How to Manage and Get the Very Best Insights
Donna Simpson
, Principal, Segmedica
Peter Simpson, Principal, Segmedica
Michelle Soto, Senior Project Director, Segmedica
___________________________________________________________________________________________________
3:30 - 3:45
Networking Break
___________________________________________________________________________________________________
5:00
Pre-Conference Workshops Conclude
___________________________________________________________________________________________________
February 4-5, 2015
Hilton Parsippany Hotel, Parsippany, NJ